NEW YORK (GenomeWeb News) – Sequenom disclosed in a filing with the US Securities and Exchange Commission on Tuesday that it has reached a settlement with Ibis Biosciences in a patent infringement suit filed by Sequenom a year ago.

Under the agreement, Ibis will pay Sequenom $1 million within 30 days and the litigation will be dismissed. Under terms of the settlement agreement, Ibis and its parent company Abbott Laboratories will receive a non-exclusive license under three mass-spectrometry-based applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.